上海醫藥(02607.HK)一季度淨利潤12.51億元 同比下降40.99%
格隆匯4月28日丨上海醫藥(02607.HK)公吿,2022年第一季度,公司主營業務繼續保持較快增長,實現營業收入568.98億元(幣種為人民幣,下同),同比增長10.27%,其中醫藥工業實現銷售收入69.28億元,同比增長7.14%;醫藥商業實現銷售收入499.70億元,同比增長10.72%。
報吿期內,公司實現歸屬於上市公司股東的淨利潤12.51億元,同比下降40.99%,主要原因為去年同期子公司變為聯營企業實現一次性特殊收益所致。歸屬於上市公司股東的扣除非經常性損益的淨利潤為12.50億元,同比增長2.98%。
醫藥工業和商業主營業務利潤繼續保持良好增長態勢,其中工業板塊貢獻利潤5.96億元,同比增長7.76%,商業板塊貢獻利潤7.46億元,同比增長27.27%,參股企業貢獻利潤1.99億元,同比下降38.11%。
報吿期內,公司研發費用投入4.48億元,同比增長7.95%,還原研發費用後歸屬於上市公司股東的扣除非經常性損益的淨利潤同比增長4.24%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.